BACKGROUND: [177Lu]Lu-PSMA radioligand therapy targets metastatic castration-resistant prostate cancer by delivering radiation to cells expressing prostate-specific membrane antigen (PSMA). This evidence concerns the gene FOLH1 and prostate carcinoma.